MELD, MELD 3.0, versus Child score to predict mortality after acute variceal hemorrhage: A multicenter US cohort
- PMID: 37695092
- PMCID: PMC10497247
- DOI: 10.1097/HC9.0000000000000258
MELD, MELD 3.0, versus Child score to predict mortality after acute variceal hemorrhage: A multicenter US cohort
Abstract
Background: Acute variceal hemorrhage is a major decompensating event in patients with cirrhosis and is associated with high 6-week mortality risk. Many prognostic models based on clinical and laboratory parameters have been developed to risk stratify patients on index bleeding presentation, including those based on the Model for End-Stage Liver Disease (MELD) and Child-Turcotte-Pugh (CTP). However, consensus on model performance remains unclear.
Methods: Using a large US multicenter cohort of hospitalized patients with cirrhosis who presented with acute variceal hemorrhage, this study evaluates, recalibrates, and compares liver severity index-based models, including the more recent MELD 3.0 model, to investigate their predictive performance on 6-week mortality. Models were also recalibrated and externally validated using additional external centers.
Results: All recalibrated MELD-based and CTP-based models had excellent discrimination to identify patients at higher risk for 6-week mortality on initial presentation. The recalibrated CTP score model maintained the best calibration and performance within the validation cohort. Patients with low CTP scores (Class A, score 5-6) were strongly associated with < 5% mortality, while high CTP score (Class C, score > 9) were associated with > 20% mortality.
Conclusion: Use of liver severity index-based models accurately predict 6-week mortality risk for patients admitted to the hospital with acute variceal hemorrhage and supports the utilization of these models in future clinical trials as well as their use in clinical practice.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Conflict of interest statement
Michael P. Curry consults and received grants from Sonic Incytes. He consults for Mallinckrodt, Albireo and Alexion and advises Pfizer. Eric Chak received grants from Target RWE and GlaxoSmithKline. Tarun Rustagi consults for Boston Scientific. Arpan Mohanty received grants from Gilead and the Kinetix Group. Brett E. Fortune consults for Gore. The remaining authors have no conflicts to report.
Figures
References
-
- FastStats – Chronic Liver Disease or Cirrhosis. Accessed January 9, 2023. https://www.cdc.gov/nchs/fastats/liver-disease.htm
-
- Garcia-Tsao G Sanyal AJ Grace ND Carey W. Practice Guidelines Committee of the American Association for the Study of Liver Diseases, the Practice Parameters Committee of the American College of Gastroenterology . Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922–938. - PubMed
-
- Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol. 2003;38:54–68. - PubMed
-
- Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–335. - PubMed
-
- Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
